Clinical Performance of the LumiraDx Platform and Intended Applications

Wednesday, July 27
2:45- 3:45 p.m.
Exhibit Hall Theater 3
Supported by LumiraDx

Overview

The COVID-19 pandemic accelerated adoption and implementation of novel and innovative technologies such as the LumiraDx SARS-CoV-2 Antigen test, a rapid microfluidic immunofluorescence assay. In contrast to the capillary action driving rapid lateral flow immunoassays, next generation microfluidic methods allow active control over many aspects of the test process including mixing, temperature, timing, incubation, magnetic capture, and signal detection. Incorporating methods common to lab analyzers into small, low-waste test strips enables the LumiraDx Platform to bring lab-comparable performance to the point of need. Attend this workshop to learn about the unique technology, clinical performance, and potential applications of the test.

Outcomes

After attending this session, participants will be able to:

  • Discuss and differentiate the next generation of rapid antigen tests as an advanced technology over lateral flow point-of-care antigen tests
  • Articulate clinical performance characteristics of the LumiraDx SARS-CoV-2 Antigen test
  • Contextualize the role of rapid microfluidic immunoassays as a resource in a variety of use-cases in response to the COVID-19 pandemic

 

Moderator

Richard H. Noel, MS
LumiraDx

Speakers

Brian DuChateau, PhD, D(ABMLI)
VP of Clinical and Scientific Affairs

Paul K. Drain, MD, MPH, FIDSA
Associate Professor, Medicine - Allergy and Infectious Dis.